Esbelta Intense Loss: FDA found four undeclared drugs

The FDA advises consumers not to purchase or use Esbelta Intense Loss, a product promoted for weight loss on websites including elegantfigure.com and possibly in some retail stores. FDA laboratory analysis confirmed four ingredients that were not listed on the label: sibutramine, desmethyl sibutramine, benzyl sibutramine, and sildenafil. This is a specific regulator warning backed by product testing. [1]

What FDA found in Esbelta Intense Loss

The FDA notice says the product was promoted and sold for weight loss online and possibly in retail. It identifies four undeclared substances, but does not publish the tested lot number, the amount of each substance, total sales, or a complete seller list. The notice also does not provide a product refund contact. Those details remain unknown; they should not be filled in with guesses. [1]

Why these ingredients raise serious safety concerns

The FDA says sibutramine was removed from the US market because of safety concerns; it can raise blood pressure or heart rate and may pose serious risks for people with heart disease, heart failure, irregular heartbeat, or prior stroke. Its two named structural relatives may carry related concerns, and the FDA warns of potentially life-threatening interactions with other medicines. Sildenafil adds a separate risk: it can interact with nitrates such as nitroglycerin and dangerously lower blood pressure. [1][2][3]

What the FDA notice does and does not establish

The FDA finding supports a clear warning about the product it tested. It does not establish that every package has an identical formula, identify the amount of each drug, or prove what a particular seller knew. The notice says the product was marketed for weight loss; it does not show that these ingredients safely or reliably produce weight loss. No verified evidence was found for a phone upsell, a “course” price, or a seller’s intent, so this review does not make those claims. These translated pages are tied to the US FDA notice and do not establish sales or regulatory status in other countries. [1]

What US buyers should do

• If you have Esbelta Intense Loss, follow FDA advice: do not buy or use it. Keep the package and label so a clinician or pharmacist can identify the product. [1]
• If you have taken it, contact a healthcare professional or pharmacist promptly and share the FDA notice, especially if you have heart or blood-pressure conditions or take prescription medicines. Do not stop prescribed treatment on your own. [1]
• For severe or urgent symptoms in the United States, call 911. Report a suspected reaction to FDA MedWatch using the reporting link in the FDA notice. [1]

Our assessment

We do not recommend Esbelta Intense Loss. FDA laboratory analysis found four undeclared drug ingredients in a product promoted for weight loss, including sibutramine and sildenafil, each with serious interaction or cardiovascular concerns. FDA explicitly advises consumers not to purchase or use it. The finding applies to the product FDA tested; it is not proof that every similar-name product or every seller is identical or acted knowingly.